<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255710</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000449652</org_study_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0169</secondary_id>
    <secondary_id>WIRB-20020304</secondary_id>
    <nct_id>NCT00255710</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer</brief_title>
  <official_title>Nonmyeloablative Bone Marrow Transplants in Hematologic Malignancies: Dose Finding Study for Post-Transplant Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy&#xD;
      before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells. It&#xD;
      also stops the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells may replace the patient's immune system and help destroy any remaining cancer&#xD;
      cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also&#xD;
      make an immune response against the body's normal cells. Giving cyclophosphamide,&#xD;
      mycophenolate mofetil, and tacrolimus after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying cyclophosphamide and/or mycophenolate mofetil with or&#xD;
      without tacrolimus to see which is the best regimen in treating patients who are undergoing a&#xD;
      donor bone marrow or stem cell transplant for hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine a minimal (short-duration) post-transplant immunosuppression regimen&#xD;
           comprising cyclophosphamide and/or mycophenolate mofetil with or without tacrolimus that&#xD;
           results in ≤ 20% incidence of grade II or higher acute graft-versus-host disease (GVHD)&#xD;
           in patients with hematologic malignancies undergoing nonmyeloablative allogeneic bone&#xD;
           marrow or peripheral blood stem cell transplantation from an HLA-identical related&#xD;
           donor.&#xD;
&#xD;
        -  Determine the post-transplant immunosuppression regimen that results in &lt; 10% incidence&#xD;
           of nonengraftment, defined as &lt; 5% donor chimerism in peripheral blood at day 60, in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the incidence and severity of acute GVHD in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Determine the frequency of mixed chimerism in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Nonmyeloablative allogeneic bone marrow transplantation (BMT) or peripheral blood stem&#xD;
           cell transplantation (PBSCT): Patients receive fludarabine IV on days -4 to -2 and&#xD;
           undergo total-body irradiation on day -1. Patients undergo allogeneic BMT on day 0 or&#xD;
           PBSCT on day 0 (and days 1 and 2, if needed). Patients receive filgrastim (G-CSF)&#xD;
           beginning on day 5 and continuing until at least day 15 or until blood counts recover.&#xD;
&#xD;
        -  Sequentially increasing levels of post-transplant immunosuppression: Cohorts of patients&#xD;
           are enrolled into 1 of the following regimens:&#xD;
&#xD;
             -  Regimen 1 (post-BMT immunosuppression): Patients receive cyclophosphamide IV on day&#xD;
                3 only.&#xD;
&#xD;
             -  Regimen 2 (post-BMT immunosuppression): Patients receive mycophenolate mofetil&#xD;
                (MMF) once on day 3 and then twice daily on days 4-32.&#xD;
&#xD;
             -  Regimen 3 (post-BMT immunosuppression): Patients receive cyclophosphamide IV on&#xD;
                days 3 and 4 and MMF twice daily on days 4-33.&#xD;
&#xD;
             -  Regimen 4 (post-PBSCT immunosuppression): Patients receive cyclophosphamide and MMF&#xD;
                as in regimen 3.&#xD;
&#xD;
             -  Regimen 5 (post-PBSCT immunosuppression): Patients receive cyclophosphamide and MMF&#xD;
                as in regimen 3 and tacrolimus twice daily on days 4-33.&#xD;
&#xD;
      Cohorts of approximately 10-20 patients receive sequentially increasing levels of&#xD;
      post-transplant immunosuppression until a minimal (short-duration) post-transplant&#xD;
      immunosuppression regimen is identified. The minimal post-transplant immunosuppression&#xD;
      regimen is defined as the regimen in which ≤ 3 of 10 or ≤ 6 of 20 patients develop grade II&#xD;
      or higher acute graft-versus-host disease AND ≤ 2 of 10 or ≤ 4 of 20 patients fail to engraft&#xD;
      60 days post-transplantation. Once the minimal post-transplant immunosuppression regimen is&#xD;
      identified, an additional 10 patients are treated with that regimen.&#xD;
&#xD;
      Patients are followed for 60 days after transplantation.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-transplant immunosuppression regimen with ≤ 20% incidence of a grade II-IV graft-versus-host-disease (GVHD) and &lt; 10% incidence of nonengraftment (&lt; 5% donor chimerism) at day 60 following transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of acute GVHD at day 60 following transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of mixed chimerism defined as any detectable donor cells at day 60 following transplant</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Stage II or III multiple myeloma&#xD;
&#xD;
               -  Amyloidosis&#xD;
&#xD;
               -  Myelofibrosis with ≥ 2 of the following high-risk features:&#xD;
&#xD;
                    -  Over 55 years of age&#xD;
&#xD;
                    -  Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
                    -  WBC &lt; 3,000/mm^3 OR &gt; 10,000/mm^3&#xD;
&#xD;
                    -  Platelet count &lt; 100,000/mm^3&#xD;
&#xD;
                    -  Cytogenetic abnormalities&#xD;
&#xD;
               -  Mycosis fungoides, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Stage IIB or III disease with evidence of histologic conversion to an&#xD;
                       aggressive lymphoma&#xD;
&#xD;
                         -  Must demonstrate chemosensitivity&#xD;
&#xD;
                    -  Stage IV disease&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria&#xD;
&#xD;
                    -  Not meeting criteria for other bone marrow transplantation (BMT) or&#xD;
                       treatment studies&#xD;
&#xD;
               -  Diagnosis of 1 of the following hematologic malignancies, for which patient is&#xD;
                  not eligible for potentially curative allogeneic BMT due to end-organ&#xD;
                  dysfunction, age 65 to 75, or the amount of prior chemotherapy:&#xD;
&#xD;
                    -  Acute myeloid or acute lymphoblastic leukemia&#xD;
&#xD;
                         -  High-risk disease in first or second (or further) complete remission&#xD;
&#xD;
                    -  Relapsed aggressive non-Hodgkin's lymphoma&#xD;
&#xD;
                         -  Not eligible for autologous or standard allogeneic BMT&#xD;
&#xD;
                    -  Hodgkin's lymphoma in second or further complete or partial remission&#xD;
&#xD;
                         -  Not eligible for autologous or standard allogeneic BMT&#xD;
&#xD;
                    -  Myelodysplastic syndromes or myelodysplastic/myeloproliferative diseases&#xD;
&#xD;
                         -  Any of the following subtypes:&#xD;
&#xD;
                              -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                              -  RAEB in transformation&#xD;
&#xD;
                              -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                              -  Any morphologic subtype with multiple chromosomal abnormalities&#xD;
&#xD;
                              -  Any subset with life-threatening cytopenias in all 3 cell lines,&#xD;
                                 defined as platelet count ≤ 20,000/mm^3, absolute neutrophil count&#xD;
                                 ≤ 500/mm^3, and reticulocyte count ≤ 50,000/mm^3&#xD;
&#xD;
                         -  Meets both of the following criteria:&#xD;
&#xD;
                              -  Less than 20% blasts by bone marrow biopsy&#xD;
&#xD;
                              -  Not eligible for standard allogeneic BMT&#xD;
&#xD;
                         -  No refractory anemia with ringed sideroblasts&#xD;
&#xD;
                         -  No 5q syndrome&#xD;
&#xD;
                    -  Stage III or IV chronic lymphocytic leukemia&#xD;
&#xD;
                         -  Not meeting criteria for other BMT studies&#xD;
&#xD;
                    -  Chronic myelogenous leukemia in first or second chronic phase&#xD;
&#xD;
                         -  Not meeting criteria for other BMT studies or treatment&#xD;
&#xD;
                    -  Stage III or IV indolent small lymphocytic or follicular lymphoma&#xD;
&#xD;
                         -  Not eligible for autologous or standard allogeneic BMT or other active&#xD;
                            protocols at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins&#xD;
&#xD;
          -  Must have an HLA-identical related donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 3.0 mg/dL&#xD;
&#xD;
          -  AST ≤ 175 U/L&#xD;
&#xD;
          -  ALT ≤ 200 U/L&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 3.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 30%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 ≥ 40% predicted&#xD;
&#xD;
          -  Forced vital capacity ≥ 40% predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol A. Huff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>November 18, 2005</study_first_submitted>
  <study_first_submitted_qc>November 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>March 16, 2010</last_update_submitted>
  <last_update_submitted_qc>March 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2010</last_update_posted>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

